• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.2011 年新型药物治疗多发性骨髓瘤的策略：欧洲视角。
Oncologist. 2011;16(4):388-403. doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26.
2
European perspective on multiple myeloma treatment strategies: update following recent congresses.欧洲视角下的多发性骨髓瘤治疗策略：近期会议后的更新。
Oncologist. 2012;17(5):592-606. doi: 10.1634/theoncologist.2011-0391. Epub 2012 May 9.
3
New treatments in multiple myeloma: beyond optimal treatment.多发性骨髓瘤的新疗法：超越最佳治疗
Ann Oncol. 2008 Jul;19 Suppl 5:v68-70. doi: 10.1093/annonc/mdn314.
4
Frontline therapy for multiple myeloma: a concise review of the evidence based on randomized clinical trials.多发性骨髓瘤的一线治疗：基于随机临床试验的证据的简明综述。
Cancer Invest. 2013 Oct;31(8):529-37. doi: 10.3109/07357907.2013.840382.
5
Bortezomib and lenalidomide effective in myeloma.硼替佐米和来那度胺对骨髓瘤有效。
Cancer Biol Ther. 2007 Jan;6(1):5.
6
Maintenance treatment in multiple myeloma.多发性骨髓瘤的维持治疗
Ann Oncol. 2008 Jun;19 Suppl 4:iv54-5. doi: 10.1093/annonc/mdn197.
7
Current multiple myeloma treatment strategies with novel agents: a European perspective.现行多发性骨髓瘤的新型药物治疗策略：欧洲视角。
Oncologist. 2010;15(1):6-25. doi: 10.1634/theoncologist.2009-0203. Epub 2010 Jan 19.
8
Novel agents in the frontline management of multiple myeloma.多发性骨髓瘤一线治疗中的新型药物
Hematol Oncol Stem Cell Ther. 2008 Oct-Dec;1(4):201-9. doi: 10.1016/s1658-3876(08)50005-7.
9
Treatment of relapsed and refractory myeloma.复发性和难治性骨髓瘤的治疗。
Curr Hematol Malig Rep. 2009 Apr;4(2):99-107. doi: 10.1007/s11899-009-0014-5.
10
Treatment paradigms for the newly diagnosed patient with multiple myeloma.新诊断的多发性骨髓瘤患者的治疗模式
Semin Hematol. 2005 Oct;42(4 Suppl 4):S16-21. doi: 10.1053/j.seminhematol.2005.10.002.

引用本文的文献

1
Multiple myeloma complicated with spinal infiltration: a case report.多发性骨髓瘤合并脊髓浸润：一例报告
Neurol Sci. 2025 Sep 10. doi: 10.1007/s10072-025-08481-4.
2
Real-World Treatment Patterns, Outcomes, and Healthcare Resource Utilization in Relapsed or Refractory Multiple Myeloma: Evidence from a Medical Record Review in France.复发或难治性多发性骨髓瘤的真实世界治疗模式、结局及医疗资源利用：来自法国一项病历回顾的证据
Adv Hematol. 2019 Jan 29;2019:4625787. doi: 10.1155/2019/4625787. eCollection 2019.
3
Thalidomide maintenance therapy in Japanese myeloma patients: a multicenter, phase II clinical trial (COMET study).沙利度胺对日本骨髓瘤患者的维持治疗：一项多中心II期临床试验（COMET研究）。
Int J Hematol. 2019 Apr;109(4):409-417. doi: 10.1007/s12185-019-02607-z. Epub 2019 Jan 31.
4
The European medicines agency review of pomalidomide in combination with low-dose dexamethasone for the treatment of adult patients with multiple myeloma: summary of the scientific assessment of the committee for medicinal products for human use.欧洲药品管理局对泊马度胺联合低剂量地塞米松治疗成年多发性骨髓瘤患者的审评：人用药品委员会科学评估总结
Oncologist. 2015 Mar;20(3):329-34. doi: 10.1634/theoncologist.2014-0073. Epub 2015 Feb 11.
5
The cost-effectiveness of initial treatment of multiple myeloma in the U.S. with bortezomib plus melphalan and prednisone versus thalidomide plus melphalan and prednisone or lenalidomide plus melphalan and prednisone with continuous lenalidomide maintenance treatment.硼替佐米联合美法仑和泼尼松与沙利度胺联合美法仑和泼尼松或来那度胺联合美法仑和泼尼松联合来那度胺维持治疗在初治多发性骨髓瘤美国的成本效益。
Oncologist. 2013;18(1):27-36. doi: 10.1634/theoncologist.2011-0380. Epub 2013 Jan 8.
6
Health care costs and resource utilization, including patient burden, associated with novel-agent-based treatment versus other therapies for multiple myeloma: findings using real-world claims data.新型药物治疗与其他疗法治疗多发性骨髓瘤的医疗成本和资源利用，包括患者负担：基于真实世界理赔数据的研究结果。
Oncologist. 2013;18(1):37-45. doi: 10.1634/theoncologist.2012-0113. Epub 2013 Jan 8.
7
Design and rationale of FOCUS (PX-171-011): a randomized, open-label, phase 3 study of carfilzomib versus best supportive care regimen in patients with relapsed and refractory multiple myeloma (R/R MM).FOCUS（PX-171-011）研究的设计和原理：卡非佐米与最佳支持治疗方案治疗复发/难治性多发性骨髓瘤（R/R MM）患者的随机、开放标签、3 期研究。
BMC Cancer. 2012 Sep 19;12:415. doi: 10.1186/1471-2407-12-415.
8
The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies.治疗性人源CD38抗体达雷妥尤单抗可增强新出现的多种药物疗法的抗骨髓瘤效果。
Blood Cancer J. 2011 Oct;1(10):e41. doi: 10.1038/bcj.2011.42. Epub 2011 Oct 28.
9
European perspective on multiple myeloma treatment strategies: update following recent congresses.欧洲视角下的多发性骨髓瘤治疗策略：近期会议后的更新。
Oncologist. 2012;17(5):592-606. doi: 10.1634/theoncologist.2011-0391. Epub 2012 May 9.
10
TRAP1 and the proteasome regulatory particle TBP7/Rpt3 interact in the endoplasmic reticulum and control cellular ubiquitination of specific mitochondrial proteins.TRAP1 和蛋白酶体调节颗粒 TBP7/Rpt3 在内质网中相互作用，并控制特定线粒体蛋白的细胞泛素化。
Cell Death Differ. 2012 Apr;19(4):592-604. doi: 10.1038/cdd.2011.128. Epub 2011 Oct 7.

本文引用的文献

1
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.来那度胺和硼替佐米治疗后复发的多发性骨髓瘤的进展和生存风险：一项多中心国际骨髓瘤工作组研究。
Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.
2
Efficacy of retreatment with immunomodulatory drugs (IMiDs) in patients receiving IMiDs for initial therapy of newly diagnosed multiple myeloma.在新诊断多发性骨髓瘤患者初始接受免疫调节药物（IMiDs）治疗时，使用 IMiDs 进行再治疗的疗效。
Blood. 2011 Aug 18;118(7):1763-5. doi: 10.1182/blood-2011-04-350009. Epub 2011 Jun 14.
3
Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3 study.硼替佐米联合沙利度胺和地塞米松与沙利度胺和地塞米松作为新诊断多发性骨髓瘤患者双自体干细胞移植前诱导治疗和巩固治疗的比较：一项随机 3 期研究。
Lancet. 2010 Dec 18;376(9758):2075-85. doi: 10.1016/S0140-6736(10)61424-9. Epub 2010 Dec 9.
4
Achievement of VGPR to induction therapy is an important prognostic factor for longer PFS in the IFM 2005-01 trial.在 IFM 2005-01 试验中，诱导治疗达到 VGPR 是无进展生存期延长的重要预后因素。
Blood. 2011 Mar 17;117(11):3041-4. doi: 10.1182/blood-2010-08-300863. Epub 2010 Nov 23.
5
Addition of thalidomide to oral melphalan/prednisone in patients with multiple myeloma not eligible for transplantation: results of a randomized trial from the Turkish Myeloma Study Group.来那度胺联合口服美法仑/泼尼松治疗不适合移植的多发性骨髓瘤患者：来自土耳其骨髓瘤研究组的一项随机试验结果。
Eur J Haematol. 2011 Jan;86(1):16-22. doi: 10.1111/j.1600-0609.2010.01524.x. Epub 2010 Nov 22.
6
Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial.硼替佐米-马法兰-泼尼松-沙利度胺序贯硼替佐米-沙利度胺维持治疗与硼替佐米-马法兰-泼尼松方案治疗初治多发性骨髓瘤的随机对照研究
J Clin Oncol. 2010 Dec 1;28(34):5101-9. doi: 10.1200/JCO.2010.29.8216. Epub 2010 Oct 12.
7
Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues.多发性骨髓瘤相关治疗周围神经病：挑战仍在继续。
Lancet Oncol. 2010 Nov;11(11):1086-95. doi: 10.1016/S1470-2045(10)70068-1.
8
Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study.硼替佐米-多柔比星-地塞米松诱导的轻链型急性肾衰竭可在多发性骨髓瘤中逆转：一项 II 期研究结果。
J Clin Oncol. 2010 Oct 20;28(30):4635-41. doi: 10.1200/JCO.2010.28.1238. Epub 2010 Sep 7.
9
Bortezomib plus dexamethasone is superior to vincristine plus doxorubicin plus dexamethasone as induction treatment prior to autologous stem-cell transplantation in newly diagnosed multiple myeloma: results of the IFM 2005-01 phase III trial.硼替佐米联合地塞米松优于长春新碱联合多柔比星联合地塞米松作为新诊断多发性骨髓瘤患者自体造血干细胞移植前的诱导治疗：IFM 2005-01 期 III 期试验结果。
J Clin Oncol. 2010 Oct 20;28(30):4621-9. doi: 10.1200/JCO.2009.27.9158. Epub 2010 Sep 7.
10
Balancing act for elderly myeloma.
Blood. 2010 Sep 2;116(9):1390-1. doi: 10.1182/blood-2010-05-285155.

2011 年新型药物治疗多发性骨髓瘤的策略：欧洲视角。

Multiple myeloma treatment strategies with novel agents in 2011: a European perspective.

机构信息

Department of Medicine I, Center of Oncology and Hematology, Wilhelminenspital, Montleartstr. 37, 1160 Vienna, Austria.

出版信息

Oncologist. 2011;16(4):388-403. doi: 10.1634/theoncologist.2010-0386. Epub 2011 Mar 26.

DOI:10.1634/theoncologist.2010-0386
PMID:21441574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3228121/
Abstract

The arrival of the novel agents thalidomide, bortezomib, and lenalidomide has significantly changed our approach to the management of multiple myeloma and, importantly, patient outcomes have improved. These agents have been investigated intensively in different treatment settings, providing us with data to make evidence-based decisions regarding the optimal management of patients. This review is an update to a previous summary of European treatment practices that examines new data that have been published or presented at congresses up to the end of 2010 and assesses their impact on treatment practices.

摘要

新型药物沙利度胺、硼替佐米和来那度胺的出现，显著改变了我们治疗多发性骨髓瘤的方法，而且患者的治疗效果也得到了改善。这些药物在不同的治疗环境中进行了深入的研究，为我们提供了数据，使我们能够根据最佳治疗方案做出基于证据的决策。本篇综述是对上一篇关于欧洲治疗实践的总结的更新，其中包括了截至 2010 年底发表或在会议上公布的新数据，并评估了它们对治疗实践的影响。